Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predictive Factors of Remission After Stopping Infliximab in Crohn's Disease
NCT00571337Phase 3Completed
- Sponsor
- GETAID
- Start
- Dec 2005
- Primary completion
- Jul 2010
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of infliximab in Crohn's disease, sponsored by GETAID. Primary endpoints: Clinical Relapse of Crohn's Disease at 1 year and Predictive Factors of Relapse at 1 year. Started Dec 2005; status: completed.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00571337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00571337.